$0.37 0.00 (%) Peregrine Pharmaceuticals Inc - NASDAQ

Jul. 26, 2016 | 04:00 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab

    Benzinga | Jan. 6, 2016 | 08:12AM EST
  2. New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma

    Benzinga | Nov. 9, 2015 | 08:05AM EST
  3. New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression

    Benzinga | Sep. 8, 2015 | 08:17AM EST
  4. US Stock Futures Tumble, China's Shanghai Plunges 8.5%

    Benzinga | Aug. 24, 2015 | 07:28AM EST
  5. AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

    Benzinga | Aug. 24, 2015 | 04:27AM EST
  6. Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab

    Benzinga | Jun. 25, 2015 | 08:30AM EST
  7. Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting

    Benzinga | Apr. 14, 2015 | 08:02AM EST
  8. Morning Market Gainers

    Benzinga | Feb. 9, 2015 | 09:48AM EST
  9. Monday Morning Movers: Achillion Up, Regulus Down Following Drug Results

    Benzinga | Feb. 9, 2015 | 09:05AM EST
  10. Phase II Clinical Data of Peregrine Pharmaceuticals' Bavituximab in Combination With Sorafenib ...

    GuruFocus | Jan. 16, 2015 | 11:02AM EST
  11. Data to Be Presented at 2014 San Antonio Breast Cancer Symposium Demonstrate Immune-Stimulatory ...

    GuruFocus | Dec. 12, 2014 | 11:03AM EST
  12. Avid Bioservices Announces Expansion of cGMP Manufacturing Capacity

    GuruFocus | Dec. 10, 2014 | 11:04AM EST
  13. Avid Bioservices Announces Expansion Of cGMP Manufacturing Capacity

    Benzinga | Dec. 10, 2014 | 08:09AM EST
  14. Earnings Scheduled For December 10, 2014

    Benzinga | Dec. 10, 2014 | 04:53AM EST
  15. Phase II Clinical Data Presented at SITC Annual Meeting Support Immunotherapeutic Mechanism of ...

    GuruFocus | Nov. 10, 2014 | 11:02AM EST
  16. Data to Be Presented at the SITC Annual Meeting Support Synergy of PS-Targeting and Anti-CTLA-4 ...

    GuruFocus | Nov. 7, 2014 | 11:03AM EST
  17. Promising Data Presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology From ...

    GuruFocus | Oct. 30, 2014 | 12:03PM EST
  18. Morning Market Movers

    Benzinga | Oct. 15, 2014 | 09:48AM EST
  19. Earnings Scheduled For September 9, 2014

    Benzinga | Sep. 9, 2014 | 05:24AM EST
  20. Earnings Scheduled For July 14, 2014

    Benzinga | Jul. 14, 2014 | 05:33AM EST
  21. Peregrine Pharmaceuticals Announces Investigator-Sponsored Trial Combining Immunotherapy Bavituximab, Ipilimumab

    Benzinga | Apr. 23, 2014 | 07:31AM EST
  22. UPDATE: Peregrine Pharma Reports Data on Bavituximab Presented at AACR Validates Immune-Stimulatory Mechanism of Action

    Benzinga | Apr. 9, 2014 | 11:05AM EST
  23. Morning Market Movers

    Benzinga | Apr. 7, 2014 | 09:40AM EST
  24. Mid Morning Gainers for March 11th, 2014

    Benzinga | Mar. 11, 2014 | 11:20AM EST
  25. Mid-Afternoon Market Update: 3D Printing Names Take a Hit From Barron's Piece as Fuel Cell Names Continue Rally

    Benzinga | Mar. 10, 2014 | 15:50PM EST
  26. Mid-Day Market Update: Chiquita Gains On Merger News; Cliffs Natural Shares Drop

    Benzinga | Mar. 10, 2014 | 12:44PM EST
  27. Mid-Morning Market Update: Markets Open Lower; McDonald's Comparable Sales Fall 0.3%

    Benzinga | Mar. 10, 2014 | 10:35AM EST
  28. Earnings Scheduled For March 7, 2014

    Benzinga | Mar. 7, 2014 | 04:58AM EST
  29. Morning Market Movers

    Benzinga | Jan. 6, 2014 | 09:57AM EST
  30. Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

    Benzinga | Dec. 30, 2013 | 07:37AM EST
  31. Earnings Scheduled For December 10, 2013

    Benzinga | Dec. 10, 2013 | 05:14AM EST
  32. Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields Enhanced Anti-Tumor Activity in Pre-Clinical Model of Melanoma

    Benzinga | Nov. 8, 2013 | 09:10AM EST
  33. Peregrine Pharma Reports Results from Phase 2 Trial of Bavituximab, Says Topline Demonstrates Signs of Anti-Tumor Activity

    Benzinga | Feb. 13, 2013 | 01:36AM EST
  34. Peregrine Pharmaceuticals Finds Its Stride Again: Exclusive Interview With MLV & Co's George Zavoico

    Benzinga | Jan. 25, 2013 | 06:56AM EST
  35. Peregrine Pharmaceuticals Soars 80% on Study Review

    Benzinga | Jan. 8, 2013 | 00:28AM EST
  36. Major Averages Record Small Losses to Start Week

    Benzinga | Jan. 7, 2013 | 09:45AM EST
  37. Morning Market Movers

    Benzinga | Jan. 7, 2013 | 02:48AM EST
  38. Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

    Benzinga | Dec. 11, 2012 | 08:03AM EST
  39. Earnings Scheduled For December 10, 2012

    Benzinga | Dec. 9, 2012 | 19:02PM EST
  40. The Week Ahead: Washington in Focus

    Benzinga | Dec. 7, 2012 | 09:37AM EST
  41. Ballots Are In: Worst CEO in the Biotech Industry Is . . .

    YCharts | Dec. 7, 2012 | 03:49AM EST
  42. Peregrine Shares Higher as Co. Reports Significant Progress in Advancing Cotara Program Into Pivotal Phase III Trial

    Benzinga | Dec. 5, 2012 | 02:19AM EST
  43. Benzinga's Microcap Movers for Wednesday October 17, 2012

    Benzinga | Oct. 17, 2012 | 14:07PM EST
  44. Milberg LLP Announces Pendency of Class Action Lawsuits Filed Against Peregrine Pharmaceuticals

    Benzinga | Oct. 5, 2012 | 09:03AM EST
  45. Benzinga Mid-Day Market Update

    Benzinga | Sep. 26, 2012 | 08:20AM EST
  46. Bronstein, Gewirtz & Grossman Announces Investigation of Peregrine Pharmaceuticals

    Benzinga | Sep. 25, 2012 | 02:33AM EST
  47. Benzinga Mid-Afternoon Market Update

    Benzinga | Sep. 24, 2012 | 09:51AM EST
  48. Mid-Day Market Losers

    Benzinga | Sep. 24, 2012 | 07:04AM EST
  49. Benzinga Mid-Day Market Update

    Benzinga | Sep. 24, 2012 | 06:58AM EST
  50. Morning Market Losers

    Benzinga | Sep. 24, 2012 | 05:08AM EST
Trading Center